Clinical factors stratifying the risk of tumor upgrading to high-grade disease in low-risk prostate cancer

被引:21
作者
Porcaro, Antonio B. [1 ]
Siracusano, Salvatore [1 ]
de Luyk, Nicola [1 ]
Corsi, Paolo [1 ]
Sebben, Marco [1 ]
Tafuri, Alessandro [1 ]
Processali, Tania [1 ]
Cerasuolo, Mattia [1 ]
Mattevi, Daniele [1 ]
Inverardi, Davide [1 ]
Cerruto, Maria A. [1 ]
Brunelli, Matteo [2 ]
Artibani, Walter [1 ]
机构
[1] Azienda Osped Univ Integrata, Osped Policlin, Univ Hosp, Ulog Clin, Verona, Italy
[2] Azienda Osped Univ Integrata, Osped Policlin, Univ Hosp, Dept Pathol, Verona, Italy
来源
TUMORI JOURNAL | 2018年 / 104卷 / 02期
关键词
Gleason score system; Prostate cancer; Tumor grade; Tumor upgrading; RADICAL PROSTATECTOMY; ACTIVE SURVEILLANCE; MEN; DISCREPANCIES; RADIATION; BIOPSY; PSA;
D O I
10.5301/tj.5000580
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To identify clinical factors stratifying the risk of tumor upgrading to increasing patterns of the tumor grading system in low-risk prostate cancer (PCa). Methods: We evaluated the records of 438 patients who underwent radical prostatectomy. Associations between clinical factors and tumor upgrading were assessed by the univariate and multivariate multinomial logistic regression model. Results: Low-risk PCa included 170 cases (38.8%) and tumor upgrading was detected in 111 patients (65.3%): 72 (42.4%) had pathology Gleason pattern (pGP) 3 + 4, 27 (15.9%) pGP 4 + 3, and 12 (7.1%) pGP 4 + 4. Prostate-specific antigen (PSA) and proportion of positive cores (P+) were independent predictors of upgrading to high-risk disease. These factors also stratified the risk of tumor upgrading to the increasing patterns of the tumor grading system. The model allowed the identification of pGP 4 + 4. The main difference between high-risk PCa and other upgraded tumors related to PSA load (odds ratio 2.4) that associated with high volume disease in the specimen. Conclusions: Low-risk PCa is a heterogeneous population with significant rates of tumor upgrading. Significant clinical predictors stratifying the risk of tumor upgrading to increasing patterns of the grading system included PSA and P+. These factors allowed the identification of the subset hiding high-grade disease requiring further investigations before delivering active treatments.
引用
收藏
页码:111 / 115
页数:5
相关论文
共 26 条
  • [1] Contemporary Grading for Prostate Cancer: Implications for Patient Care
    Brimo, Fadi
    Montironi, Rodolfo
    Egevad, Lars
    Erbersdobler, Andreas
    Lin, Daniel W.
    Nelson, Joel B.
    Rubin, Mark A.
    van der Kwast, Theo
    Amin, Mahul
    Epstein, Jonathan I.
    [J]. EUROPEAN UROLOGY, 2013, 63 (05) : 892 - 901
  • [2] Caster JM, 2015, PHYS, V92, P244
  • [3] Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation
    Chun, Felix K. -H.
    Briganti, Alberto
    Shariat, Shahrokh F.
    Graefen, Markus
    Montorsi, Francesco
    Erbersdobler, Andreas
    Steuber, Thomas
    Salonia, Andrea
    Currlin, Eike
    Scattoni, Vincenzo
    Friedrich, Martin G.
    Schlomm, Thorsten
    Haese, Alexander
    Michl, Uwe
    Colombo, Renzo
    Heinzer, Hans
    Friedrich, Martin G.
    Schlomm, Thorsten
    Haese, Alexander
    Michl, Uwe
    Colombo, Renzo
    Heinzer, Hans
    Valiquette, Luc
    Rigatti, Patrizio
    Roehrborn, Claus G.
    Huland, Hartwig
    Karakiewicz, Pierre I.
    [J]. BJU INTERNATIONAL, 2006, 98 (02) : 329 - 334
  • [4] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [5] Clinical predictors of upgrading to gleason grade 4 or 5 disease at radical prostatectomy: Potential implications for patient selection for radiation and androgen suppression therapy
    D'Amico, AV
    Renshaw, AA
    Arsenault, L
    Schultz, D
    Richie, JP
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (04): : 841 - 846
  • [6] Dahabreh IJ, 2012, ANN INTERN MED, V156, P582, DOI [10.7326/0003-4819-156-8-201204170-00009, 10.7326/0003-4819-156-8-201204170-00397]
  • [7] The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Epstein, JI
    Allsbrook, WC
    Amin, MB
    Egevad, LL
    Bastacky, S
    Beltrán, AL
    Berner, A
    Billis, A
    Boccon-Gibod, L
    Cheng, L
    Civantos, F
    Cohen, C
    Cohen, MB
    Datta, M
    Davis, C
    Delahunt, B
    Delprado, W
    Eble, JN
    Foster, CS
    Furusato, M
    Gaudin, PB
    Grignon, DJ
    Humphrey, PA
    Iczkowski, KA
    Jones, EC
    Lucia, S
    McCue, PA
    Nazeer, T
    Oliva, E
    Pan, CC
    Pizov, G
    Reuter, V
    Samaratunga, H
    Sebo, T
    Sesterhenn, I
    Shevchuk, M
    Srigley, JR
    Suzigan, S
    Takahashi, H
    Tamboli, P
    Tan, PH
    Têtu, B
    Tickoo, S
    Tomaszewski, JE
    Troncoso, P
    Tsuzuki, T
    True, LD
    van der Kwast, T
    Wheeler, TM
    Wojno, KJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1228 - 1242
  • [8] A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
    Epstein, Jonathan I.
    Zelefsky, Michael J.
    Sjoberg, Daniel D.
    Nelson, Joel B.
    Egevad, Lars
    Magi-Galluzzi, Cristina
    Vickers, Andrew J.
    Parwani, Anil V.
    Reuter, Victor E.
    Fine, Samson W.
    Eastham, James A.
    Wiklund, Peter
    Han, Misop
    Reddy, Chandana A.
    Ciezki, Jay P.
    Nyberg, Tommy
    Klein, Eric A.
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 428 - 435
  • [9] Expectant Management for Men With Early Stage Prostate Cancer
    Filson, Christopher P.
    Marks, Leonard S.
    Litwin, Mark S.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (04) : 264 - 282
  • [10] Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens
    Fukagai, T
    Namiki, T
    Namiki, H
    Carlile, RG
    Shimada, M
    Yoshida, H
    [J]. PATHOLOGY INTERNATIONAL, 2001, 51 (05) : 364 - 370